DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Blanke CD, Rankin C, Demetri GD. , et al.
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
J Clin Oncol 2008;
26 (04) 626-632
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.